Biocon Limited has released its quarterly certificate confirming the utilization of proceeds from Commercial Paper (CP) for the quarter ended March 31, 2026. The company confirmed that all funds were used for designated purposes, including equity and debenture-related activities for its subsidiaries. Additionally, the company reported a total CP issuance of ₹200 Crores for the calendar year up to the end of Q4.
Quarterly Compliance and Fund Utilization
Biocon Limited has verified its adherence to all listing conditions regarding the issuance of Commercial Paper for the quarter ending March 31, 2026. The company’s leadership confirmed that all funds raised were channeled strictly toward the purposes disclosed in their listing applications. Furthermore, the company maintains a “Standard” asset classification for its fund-based facilities from banks and financial institutions.
Details of CP Issuance
During the period under review, the company managed its debt obligations effectively. Notably, the company successfully executed a buy-back and fulfilled payment obligations for its outstanding Commercial Papers on January 30, 2026. Key issuance highlights include:
- December 22, 2025: Issuance of ₹1,800 Crore in CPs for the acquisition of equity shares in a subsidiary.
- January 2, 2026: Issuance of ₹200 Crore in CPs for the redemption and acquisition of subsidiary debentures.
Financial Outlook
The total issuance of CPs for the calendar year up to the end of the March 2026 quarter stood at ₹200 Crores. Biocon Limited has confirmed that there have been no material changes in the company’s financial status that would negatively impact its current credit ratings, ensuring continued stability for its investors and stakeholders.
Source: BSE
